Chronic obstructive pulmonary disease (COPD) is a major cause of death and disability
worldwide. Inhaled bronchodilators are the mainstay of COPD pharmacological treatment …

The topic of 24-hour management of COPD is related to day-to-night symptoms
management, specific follow-up and patients' adherence to therapy. COPD symptoms …

Aims Glycopyrronium bromide (NVA 237) is a once‐daily long‐acting muscarinic antagonist
recently approved for the treatment of chronic obstructive pulmonary disease. In this study …

Long-acting muscarinic antagonists (LAMAs), along with long-acting β2-agonists (LABAs),
are the mainstay for treatment of patients with COPD. Glycopyrrolate, or glycopyrronium …

This multicentre, double-blind, randomised, placebo-controlled, crossover study aimed to
determine the dose-response of the long-acting muscarinic antagonist (LAMA) …

Inhaled glycopyrronium bromide (Seebri® Breezhaler® capsules; NVA237) is a once-daily,
long-acting muscarinic receptor antagonist (LAMA) that is approved in several countries …

Background The purpose of this study was to confirm the efficacy and safety of twice-daily
glycopyrrolate 15.6 µg, a long-acting muscarinic antagonist, in patients with stable …

Bronchodilators are mainstay for the symptomatic treatment of chronic obstructive pulmonary
disease (COPD) and the introduction of long-acting bronchodilators has led to an …

Night-time and early morning symptoms are common and uncomfortable in many patients
with COPD, and likely to negatively influence their long-term outcomes. However, it is still …

Background: The objective of the FLIGHT3 study was to evaluate the long-term safety and
efficacy of indacaterol/glycopyrrolate*(IND/GLY) versus an active comparator, IND, in …